Self-scheduling to be the norm by 2019

Online self-scheduling of physician appointments has the potential to save $3.2 billion, according to a report from Accenture.

The savings are due to eliminating time spent on the phone keeping after patients to schedule, change or cancel appointments. The report predicts that by the end of 2019, two-thirds of U.S. health systems will offer patients the ability to self-schedule appointments online. Those that do will be able to divert 80 percent of their appointment volume, on average, through patient self-scheduling.

The time difference is just under one minute spent online compared with eight minutes on the phone. The patients of 40 percent of the 100 largest health systems booked about half of their appointments online. Only 10 percent of smaller healthcare practices offered online self-scheduling. The report also found that 11 percent of all U.S. health systems allow self-scheduling for appointments and only 2.4 percent of their patients used it.

“Just as consumers use online tools to book restaurant reservations or request a cab, patients want the same experience in self-booking a doctor’s appointment,” said Dipak Patel, managing director of Accenture’s patient access solutions in a release. “Evidence also shows health systems can use self-scheduling tools to boost appointment capacity, reduce costs and/or increase productivity.”

Access the report.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.